Variable | Univariate model | ||
HR | 95% CI | P value | |
Sex (male) | |||
Age at diagnosis of PsA in years | |||
Sacroiliitis grade* | 0.899 | (0.466 to 1.733) | 0.751 |
Enthesitis | 0.940 | (0.121 to 7.342) | 0.953 |
Elevated ESR | 0.626 | (0.230 to 1.708) | 0.360 |
Nail lesion | 0.826 | (0.319 to 2.141) | 0.694 |
PASI | 1.030 | (0.960 to 1.106) | 0.408 |
Uveitis | 2.130 | (0.786 to 5.769) | 0.137 |
HLA-B*27 | 1.069 | (0.394 to 2.901) | 0.896 |
NSAIDS | 1.009 | (0.434 to 2.346) | 0.983 |
DMARDS | 0.825 | (0.341 to 1.993) | 0.669 |
Biologics | 1.137 | (0.381 to 3.392) | 0.818 |
*The sacroiliac joint with the highest grade was used preferentially for analysis.
DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; PASI, psoriasis area and severity index; PsA, psoriatic arthritis.